PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC April 10, 2017 PSA doubling time (PSADT) among patients with castration-resistant prostate cancer (CRPC) strongly predicts their risk for metastatic disease and all-cause and cancer-specific mortality, according to a new study.Read more.Source: Renal and Urology News Prostate Cancer News
PSA doubling time (PSADT) among patients with castration-resistant prostate cancer (CRPC) strongly predicts their risk for metastatic disease and all-cause and cancer-specific mortality, according to a new study.Read more.Source: Renal and Urology News
